A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) Interval

A Randomised, Partially Double Blind, Placebo and Positive Controlled, 4 Way Crossover Study to Evaluate the Effect of Icosabutate (NST 4016) on the QT/QTc Interval in Healthy Subjects

This is a Phase 1, single centre, randomised, double blind (except for moxifloxacin), placebo and positive controlled, 4 way crossover study assessing the ECG effects of therapeutic and supratherapeutic doses of icosabutate in healthy male and female subjects.

Inclusion Criteria:

• 1. Males or females, of any race, between 18 and 55 years of age, inclusive, at Screening.
• 2. Body mass index (BMI) between 18.0 and 33.0 kg/m2, inclusive, at Screening
• 3. In good health

Exclusion Criteria:

• 1. An uninterpretable or abnormal ECG at Screening and/or Check in
• 2. History of risk factors for Torsades de Pointes
• 3. sustained supine systolic blood pressure >140 mmHg or <90 mmHg
• 4. Unstable cardiovascular disease, including recent myocardial infarction or cardiac arrhythmia.
• 5. Female subjects who are pregnant (or planning to become pregnant within 90 days after the final dose administration) or are currently lactating
• 6. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study